Aptus Pharma receives BSE in-principle approval for preferential equity issue
Aptus Pharma Ltd · Pharmaceuticals & Biotechnology
What the filing says
- BSE Limited granted in-principle approval on October 30, 2026
- Approval under Regulation 28(1) of SEBI (LODR) Regulations, 2015
- Preferential issue was approved by shareholders on September 14, 2026
Why it's rated notable: The filing reports only an in-principle approval from BSE for a preferential issue of equity shares, which is non-binding and states no issue size or amount, so the level stays at the medium default.
Original filing
Receipt Of In-Principle Approval For Preferential Issue
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other fundraise / allotment filings this fortnight
- Ratnaveer Precision Engineering Ltd Q2 FY27 Revenue up 35%, PAT up 56%
- Midwest Energy's board accepts MIDC offers for Butibori leasehold land
- Sammaan Capital allots 8.69 crore shares on conversion of Tranche I Warrants to promoter
- Ola Electric Rights Issue of up to ₹1,000 crore closes on October 30, 2026
- Manaksia Coated Metals announces QIP issue approval and floor price ₹127.01
- D. P. Abhushan Ltd holds EOGM approving preferential issue of shares and warrants
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.